- The Trump administration is moving forward with new rules that would require drug companies to disclose their prices, rejecting the industry’s efforts to preempt those regulations
- The “list price” of prescription drugs doesn’t mean anything to patients.
- Alex Azar is “sticking it” to PhRMA, pharma’s trade organization.